To hear about similar clinical trials, please enter your email below

Trial Title: Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma

NCT ID: NCT01178658

Condition: Non-Hodgkin Lymphoma

Conditions: Official terms:
Lymphoma
Cytarabine
Etoposide
Melphalan
Busulfan

Study type: Interventional

Study phase: Phase 2

Overall status: Unknown status

Study design:

Allocation: Non-Randomized

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Busulfan, etoposide, cytarabine, and melphalan
Description: Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
Arm group label: BuEAM

Summary: The purpose of this study is to evaluate the efficacy and toxicity of busulfan, etoposide, cytarabine and melphalan (BuEAM) as a conditioning for autologous stem cell transplantation in patients with non-Hodgkin lymphoma.

Detailed description: High-dose conditioning regimens commonly used in patients with non-Hodgkin lymphoma are BEAM (BCNU, etoposide, cytarabine, and melphalan), BEAC (BCNU, etoposide, cytarabine, and cyclophosphamide), CBV (cyclophosphamide, carmustine, and etoposide), and combination regimen with total body irradiation. Three-year progression free survival of patients with non-Hodgkin lymphoma received above high-dose chemotherapy followed by autologous stem cell rescue was reported as 40-50%, which is still unsatisfactory. Busulfan (Bu)-based preparative regimens, which are commonly used with allogeneic stem cell transplantation have also been studied with autologous stem cell transplantation for lymphomas. The development of intravenous busulfan achieved 100% bioavailability bypassing the oral route and increased safety and reliability of generating therapeutic busulfan levels, maximizing efficacy. Recently, one prospective study showed that a combination conditioning regimen of intravenous busulfan, cyclophosphamide, and etoposide was found to be well tolerated and seemed to be effective in patients with aggressive non-Hodgkin lymphoma. Another prospective study for patients with multiple myeloma showed that intravenous busulfan plus melphalan conditioning regimen made no grade 3-4 non-hematologic complication.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Patients with a high-intermediate/high risk international prognostic index at a diagnosis or with salvage chemotherapy-sensitive relapse/refractory non-Hodgkin lymphoma - Patients with histologically confirmed T cell or NK cell lymphoma at diagnosis - Patients who have not received therapy with high-dose chemotherapy and stem cell transplantation - Life expectation of at least 3 months - ECOG performance status ≤ 2 - Adequate hepatic function (serum bilirubin less than 2.0 mg/dL, AST and ALT less than three times the upper normal limit) - Adequate renal function (serum creatinine less than 2.0 mg/dL). - Adequate cardiac function (ejection fraction ≥ 45% on MUGA scan or echocardiogram). - Adequate bone marrow function (ANC ≥ 1,000/mm3 and platelet count ≥ 75,000/mm3). - All patients are fully informed about the nature and purpose of this study and informed consent should be given before the start of treatment. All patients should fully understand the right of trial abandon without any disadvantage Exclusion Criteria: - Patients with central nervous system involvement of lymphoma - Patients positive for human immunodeficiency virus - Pregnant or breast feeding woman - Young woman without pregnancy test prior to treatment or pregnancy test reveals positive. - Young woman without a reliable and proper contraceptive method - Man being not willing to contraception - Concurrent history of neoplasm other than non-Hodgkin lymphoma with life expectancy less than 3 months (except for curatively treated non-melanoma skin cancer or in-situ uterine cervix cancer). - History of clinically significant cardiac dysfunction (e.g. congestive heart failure, symptomatic coronary artery disease, medically uncontrolled arrhythmia) or myocardial infarction within 12 months - A psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible. - Significant infection or uncontrolled bleeding - Enrollment of other clinical trials within 4 weeks prior to treatment - Any preexisting medical condition of sufficient severity to prevent full compliance with the study - Patient being not willing to or unable to obey study protocol

Gender: All

Minimum age: 15 Years

Maximum age: 65 Years

Healthy volunteers: No

Locations:

Facility:
Name: Inje University Busan Paik Hospital, Inje University College of Medicine

Address:
City: Busan
Zip: 614-735
Country: Korea, Republic of

Status: Recruiting

Contact:
Last name: Won Sik Lee

Phone: +82-51-890-6407
Email: drlee112@hanafos.com

Investigator:
Last name: Won Sik Lee
Email: Principal Investigator

Facility:
Name: Seoul National University Hospital, Seoul National University College of Medicine

Address:
City: Seoul
Zip: 110-744
Country: Korea, Republic of

Status: Recruiting

Contact:
Last name: Sung-Soo Yoon

Phone: +82-2-2072-3079
Email: ssysmc@snu.ac.kr

Contact backup:
Last name: Ji-Won Kim

Phone: +82-11-9010-0427
Email: werbinig@gmail.com

Investigator:
Last name: Byoung Kook Kim
Email: Sub-Investigator

Investigator:
Last name: Seonyang Park
Email: Sub-Investigator

Investigator:
Last name: Sung-Soo Yoon
Email: Principal Investigator

Investigator:
Last name: Inho Kim
Email: Sub-Investigator

Facility:
Name: Severance Hospital, Yonsei University College of Medicine

Address:
City: Seoul
Zip: 120-752
Country: Korea, Republic of

Status: Recruiting

Contact:
Last name: Jin Seok Kim
Email: hemakim@yuhs.ac

Investigator:
Last name: Jin Seok Kim
Email: Principal Investigator

Facility:
Name: Asan Medical Center, University of Ulsan College of Medicine

Address:
City: Seoul
Zip: 138-736
Country: Korea, Republic of

Status: Recruiting

Contact:
Last name: Je Hwan Lee
Email: jhlee3@amc.seoul.kr

Investigator:
Last name: Je Hwan Lee
Email: Principal Investigator

Facility:
Name: Ulsan University Hospital, University of Ulsan College of Medicine

Address:
City: Ulsan
Zip: 682-714
Country: Korea, Republic of

Status: Recruiting

Contact:
Last name: Hawk Kim

Investigator:
Last name: Hawk Kim
Email: Principal Investigator

Start date: July 2010

Lead sponsor:
Agency: Seoul National University Hospital
Agency class: Other

Collaborator:
Agency: Inje University
Agency class: Other

Collaborator:
Agency: Severance Hospital
Agency class: Other

Collaborator:
Agency: Asan Medical Center
Agency class: Other

Collaborator:
Agency: Ulsan University Hospital
Agency class: Other

Source: Seoul National University Hospital

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT01178658

Login to your account

Did you forget your password?